相关实验视频

Updated: Jun 20, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

亚特梅西亚 argyi多醇通过调节肠道微生物群的结构组成,减轻小鼠DSS诱导的结肠炎

Huaqiang Zhang¹, Zhonghua Hao², Ruya Zhang²

¹College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450000, Henan province, PR China; Henan High Tech Industry Co., Ltd., Henan Academy of Sciences, Zhengzhou 450000, PR China; Ministry of Education Key Laboratory for Animal Pathogens and Biosafety, Zhengzhou 450000, Henan province, PR China.

Phytomedicine : international journal of phytotherapy and phytopharmacology

|July 20, 2024

概括

艺术 argyi多 (AAPs) 通过调节肠道微生物群和促进有益的脂肪酸合成来缓解结肠炎. 这项研究为使用AAP治疗性结肠炎提供了基础.

科学领域:

胃肠病学胃肠病学
微生物学微生物学
药理学药理学是指药理学的学科.

背景情况:

肠道微生物不平衡与结肠炎和性结肠炎 (UC) 有关.
阿尔提米西亚阿尔吉表现出抗炎性质,但其在UC中的机制和对肠道微生物群的影响仍然不清楚.

研究的目的:

研究Artemisia argyi多 (AAPs) 是否可以通过改变肠道微生物群的组成和功能来缓解性结肠炎 (UC).

主要方法:

在使用DSS的小鼠中诱导了性结肠炎;AAPs是口服的.
炎症性,氧化应激和屏障蛋白表达通过西部涂抹和免疫光分析.
评估了肠道微生物群结构和代谢物,以及便微生物群移植 (FMT),以确认微生物群依赖的影响.

主要成果:

AAP和FMT改善了DSS诱导的结肠损伤和减少了炎症标志物 (IL-6,TNF-α).
AAPs增加了抗氧化剂 (Nrf2,NQO-1,HO-1) 和屏障蛋白 (Claudin-1,Occludin,ZO-1,MUC2) 的表达.
AAPs促进了有益的细菌 (例如,Butyricimonas,Lactobacillus) 和有益的代谢物 (酸,黄油酸,酸).

结论:

通过调节肠道微生物群结构,AAPs可以改善DSS诱导的大肠炎的结肠损伤.
AAPs在肠道中促进有益的脂肪酸合成,为性结肠炎提供了潜在的治疗策略.

关键词:

亚特梅西亚阿尔吉 (Artemisia argyi) 聚类的多.便微生物群移植便微生物群移植我们的肠道微生物群.性结肠炎是一种

更多相关视频

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Published on: February 1, 2012

相关概念视频

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...